A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
Patients with recurrent or metastatic cervical cancer have limited therapeutic options. Here the authors report efficacy and safety of camrelizumab (anti-PD-1 antibody) in combination with famitinib (anti-angiogenic agent) in pre-treated recurrent or metastatic squamous cervical cancer.
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-12-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-35133-4 |
| _version_ | 1828277751149232128 |
|---|---|
| author | Lingfang Xia Qi Zhou Yunong Gao Wenjing Hu Ge Lou Hong Sun Jianqing Zhu Jin Shu Xianfeng Zhou Rong Sun Xiaohua Wu |
| author_facet | Lingfang Xia Qi Zhou Yunong Gao Wenjing Hu Ge Lou Hong Sun Jianqing Zhu Jin Shu Xianfeng Zhou Rong Sun Xiaohua Wu |
| author_sort | Lingfang Xia |
| collection | DOAJ |
| description | Patients with recurrent or metastatic cervical cancer have limited therapeutic options. Here the authors report efficacy and safety of camrelizumab (anti-PD-1 antibody) in combination with famitinib (anti-angiogenic agent) in pre-treated recurrent or metastatic squamous cervical cancer. |
| first_indexed | 2024-04-13T07:19:19Z |
| format | Article |
| id | doaj.art-b68826bcc1284eef9a80d3a0217d0034 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-13T07:19:19Z |
| publishDate | 2022-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-b68826bcc1284eef9a80d3a0217d00342022-12-22T02:56:39ZengNature PortfolioNature Communications2041-17232022-12-011311910.1038/s41467-022-35133-4A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinomaLingfang Xia0Qi Zhou1Yunong Gao2Wenjing Hu3Ge Lou4Hong Sun5Jianqing Zhu6Jin Shu7Xianfeng Zhou8Rong Sun9Xiaohua Wu10Department of Gynecological Oncology, Fudan University Shanghai Cancer CenterDepartment of Gynaecology, Affiliated Tumor Hospital of Chongqing UniversityDepartment of Gynaecology, Beijing Cancer HospitalDepartment of Oncology, Nanjing Drum Tower HospitalDepartment of Gynaecology, Affiliated Tumor Hospital of Harbin Medical UniversityDepartment of Gynecologic Oncology, Obstetrics & Gynecology Hospital of Fudan UniversityDepartment of Gynecological Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)Department of Gynaecology, Affiliated Tumor Hospital of Chongqing UniversityDepartment of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd.Department of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd.Department of Gynecological Oncology, Fudan University Shanghai Cancer CenterPatients with recurrent or metastatic cervical cancer have limited therapeutic options. Here the authors report efficacy and safety of camrelizumab (anti-PD-1 antibody) in combination with famitinib (anti-angiogenic agent) in pre-treated recurrent or metastatic squamous cervical cancer.https://doi.org/10.1038/s41467-022-35133-4 |
| spellingShingle | Lingfang Xia Qi Zhou Yunong Gao Wenjing Hu Ge Lou Hong Sun Jianqing Zhu Jin Shu Xianfeng Zhou Rong Sun Xiaohua Wu A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma Nature Communications |
| title | A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma |
| title_full | A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma |
| title_fullStr | A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma |
| title_full_unstemmed | A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma |
| title_short | A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma |
| title_sort | multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma |
| url | https://doi.org/10.1038/s41467-022-35133-4 |
| work_keys_str_mv | AT lingfangxia amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT qizhou amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT yunonggao amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT wenjinghu amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT gelou amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT hongsun amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT jianqingzhu amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT jinshu amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT xianfengzhou amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT rongsun amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT xiaohuawu amulticenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT lingfangxia multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT qizhou multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT yunonggao multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT wenjinghu multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT gelou multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT hongsun multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT jianqingzhu multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT jinshu multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT xianfengzhou multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT rongsun multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma AT xiaohuawu multicenterphase2trialofcamrelizumabplusfamitinibforwomenwithrecurrentormetastaticcervicalsquamouscellcarcinoma |